首页> 美国卫生研究院文献>Aging (Albany NY) >LncRNA NEAT1/miR-129/Bcl-2 signaling axis contributes to HDAC inhibitor tolerance in nasopharyngeal cancer
【2h】

LncRNA NEAT1/miR-129/Bcl-2 signaling axis contributes to HDAC inhibitor tolerance in nasopharyngeal cancer

机译:LNCRNA Neat1 / miR-129 / Bcl-2信号轴有助于鼻咽癌的HDAC抑制剂耐受性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Histone deacetylase inhibitors (HDACis) - based therapeutic drug tolerance is one of the principal factors of poor prognosis of patients with nasopharyngeal cancer (NPC). Mechanisms of tolerance to HDACis are not well understood. Nowadays, dysregulation of long non-coding RNAs (LncRNAs) and microRNAs (miRNAs) has been reported to provide beneficial or inhibitory effects in drug-tolerance in various cancers. Herein, we established the HDAC inhibitor (SAHA)-tolerant NPC cell sublines, which had decreased apoptosis in response to SAHA treatment. We observed that the expression of miR-129 was significantly reduced in SAHA-tolerant NPC cells. Manipulating the expression of miR-129 overcame SAHA tolerance, and enhanced the SAHA-induced apoptosis. In terms of miR-129 downregulation, we identified that NEAT1 suppresses miR-129 expression. NEAT1 was found to be upregulated in SAHA tolerance cells. The depletion of NEAT1 phenocopied the effect of miR-129 overexpression, which also enhanced SAHA-induced apoptosis. Bcl-2 was the downstream target of miR-129 and contributed to SAHA tolerance in NPC. Our in vivo xenograft experiment confirmed that the administration of miR-129 or inhibition of Bcl-2 overcame the SAHA tolerance in NPC. In conclusion, NEAT1 increases in NPC tissues and manages to facilitate SAHA tolerance by modulating the miR-129/Bcl-2 axis, providing novel therapeutic targets for NPC treatment.
机译:组蛋白脱乙酰酶抑制剂(HDACIS)的治疗药物耐受性是鼻咽癌(NPC)患者预后不良的主要因素之一。对HDACIS的耐受机制尚不清楚。如今,据报道,长期非编码RNA(LNCRNA)和MicroRNA(miRNA)的失调为各种癌症的耐药性提供有益或抑制作用。在此,我们建立了HDAC抑制剂(SAHA) - 响应SAHA治疗的细胞凋亡降低了细胞凋亡。我们观察到MiR-129的表达在蜂耐性NPC细胞中显着降低。操纵miR-129克服萨哈耐受的表达,增强了萨哈诱导的细胞凋亡。就MiR-129下调而言,我们确定了Neat1抑制了miR-129表达。发现Neat1在莎哈耐受性细胞中上调。 Neat1的枯竭验证MiR-129过表达的效果,这也增强了萨哈诱导的细胞凋亡。 BCL-2是MiR-129的下游靶标,并导致NPC的撒哈岛耐受性。我们的体内异种移植实验证实,MIR-129的给药或BCL-2的抑制克服了NPC中的撒哈拉耐受性。总之,Neat1增加了NPC组织,并通过调节MiR-129 / Bcl-2轴来促进撒哈拉耐受,为NPC治疗提供新的治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号